China’s contract drug manufacturing industry is facing growing uncertainty as United States pharmaceutical companies accelerate efforts to bring production back onshore and restructure global supply chains. The shift reflects broader geopolitical tensions and strategic concerns around dependency on overseas manufacturing, particularly in critical
Researchers in China have developed an experimental technique that could significantly extend how long organs remain viable for transplantation, potentially reshaping the global organ transplant system. According to a peer reviewed study published in the Journal of Medical Devices, the method allows organs
China has approved its first implantable brain computer interface system, marking a major step in the country’s expanding neurotechnology sector. The device was developed by Neuracle Medical Technology and is designed to help patients with spinal cord injuries regain control of hand movements.
US pharmaceutical giant Eli Lilly has announced plans to invest an additional 3 billion US dollars in China over the next decade, reinforcing its long term commitment to one of the world’s fastest growing healthcare markets. The new investment will focus on strengthening
Mainland Chinese investors are increasingly fueling momentum in Hong Kong listed biotechnology and pharmaceutical companies following a recent adjustment to the Stock Connect southbound trading list. The update now allows mainland investors to trade shares in more than a dozen additional biotech firms
China has approved a new GLP 1 based drug developed by Pfizer for long term weight management in adults who are overweight or obese, marking another step in the rapid expansion of the country’s metabolic health treatment market. The approval allows the injectable
Hong Kong listed biotechnology company Insilico Medicine has expanded its global footprint through a new partnership in the United Arab Emirates aimed at accelerating artificial intelligence driven drug discovery. The agreement was signed with the UAE’s national drug regulator during a major healthcare
China and Hong Kong are being encouraged to relax listing requirements for biotechnology companies as investors seek to accelerate growth in the healthcare sector. Venture capital leaders and industry participants argue that regulatory adjustments could help innovative biotech firms gain faster access to
China’s biotechnology sector has recorded a sharp rise in international licensing deals during the opening months of 2026, highlighting the country’s growing influence in global pharmaceutical research and drug development. The total value of outlicensing agreements signed by Chinese biotech companies in the
Diagnostics startup Droplet Biosciences has announced a collaboration with Nvidia to accelerate the processing of genomic data used in post surgery cancer testing, aiming to significantly shorten the time patients wait for critical results. The company is integrating Nvidia’s GPU accelerated computing infrastructure,
